PL2734552T3 - Hamujące monoklonalne przeciwciała skierowane przeciwko czynnikowi xii/xiia i ich zastosowanie - Google Patents

Hamujące monoklonalne przeciwciała skierowane przeciwko czynnikowi xii/xiia i ich zastosowanie

Info

Publication number
PL2734552T3
PL2734552T3 PL12735916.4T PL12735916T PL2734552T3 PL 2734552 T3 PL2734552 T3 PL 2734552T3 PL 12735916 T PL12735916 T PL 12735916T PL 2734552 T3 PL2734552 T3 PL 2734552T3
Authority
PL
Poland
Prior art keywords
xiia
monoclonal antibodies
antibodies against
factor xii
against factor
Prior art date
Application number
PL12735916.4T
Other languages
English (en)
Inventor
Con Panousis
Veronika Rayzman
Andrew Nash
Michael Wilson
Stefan Schmidbauer
Marc Nolte
Original Assignee
Csl Behring Gmbh
Csl Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11175105A external-priority patent/EP2548892A1/en
Application filed by Csl Behring Gmbh, Csl Limited filed Critical Csl Behring Gmbh
Publication of PL2734552T3 publication Critical patent/PL2734552T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21038—Coagulation factor XIIa (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
PL12735916.4T 2011-07-22 2012-07-20 Hamujące monoklonalne przeciwciała skierowane przeciwko czynnikowi xii/xiia i ich zastosowanie PL2734552T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161510801P 2011-07-22 2011-07-22
EP11175105A EP2548892A1 (en) 2011-07-22 2011-07-22 Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
EP12153310 2012-01-31
PCT/EP2012/064322 WO2013014092A1 (en) 2011-07-22 2012-07-20 Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses

Publications (1)

Publication Number Publication Date
PL2734552T3 true PL2734552T3 (pl) 2025-03-24

Family

ID=47600530

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12735916.4T PL2734552T3 (pl) 2011-07-22 2012-07-20 Hamujące monoklonalne przeciwciała skierowane przeciwko czynnikowi xii/xiia i ich zastosowanie

Country Status (27)

Country Link
US (5) US9518127B2 (pl)
EP (2) EP4516811A3 (pl)
JP (1) JP6253578B2 (pl)
KR (1) KR102042982B1 (pl)
CN (1) CN103687878B (pl)
AU (1) AU2012289001B2 (pl)
BR (1) BR112014001104B1 (pl)
CA (1) CA2841185C (pl)
CY (1) CY2025019I1 (pl)
DK (1) DK2734552T3 (pl)
ES (1) ES3005912T3 (pl)
FI (2) FI2734552T3 (pl)
FR (1) FR25C1026I1 (pl)
HR (1) HRP20250164T1 (pl)
HU (2) HUE070002T2 (pl)
IL (2) IL230564B2 (pl)
LT (2) LT2734552T (pl)
MX (1) MX347454B (pl)
NL (1) NL301332I2 (pl)
NO (1) NO2025031I1 (pl)
PL (1) PL2734552T3 (pl)
PT (1) PT2734552T (pl)
RS (1) RS66465B1 (pl)
RU (1) RU2660370C2 (pl)
SI (1) SI2734552T1 (pl)
SM (1) SMT202500041T1 (pl)
WO (1) WO2013014092A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6253578B2 (ja) * 2011-07-22 2017-12-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
KR102403299B1 (ko) * 2013-03-08 2022-06-03 체에스엘 베링 게엠베하 원격 허혈-재관류 손상의 치료 및 예방
JP2017501968A (ja) * 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
CN106456778A (zh) 2014-06-18 2017-02-22 德国杰特贝林生物制品有限公司 在神经创伤性病患中使用因子xii抑制剂进行治疗
US11390687B2 (en) * 2015-01-02 2022-07-19 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and Factor XII
JP7068160B2 (ja) * 2015-07-21 2022-05-16 武田薬品工業株式会社 第ＸＩＩａ因子のモノクローナル抗体阻害剤
RU2021129189A (ru) * 2016-01-22 2021-11-15 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
AU2017247004B2 (en) * 2016-04-06 2022-07-07 Csl Limited Method of treating atherosclerosis
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
AU2018382222B2 (en) * 2017-12-15 2025-09-04 Csl Limited Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
MA52966A (fr) * 2018-06-19 2021-04-28 Regeneron Pharma Anticorps anti-facteur xii/xiia et leurs utilisations
CN113423465B (zh) * 2018-11-28 2024-12-06 俄勒冈健康与科学大学 治疗性的因子xii抗体
CN114072425A (zh) * 2019-06-12 2022-02-18 杰特创新股份有限公司 可溶性补体受体1型变体缀合物及其用途
AU2020396054A1 (en) * 2019-12-03 2022-07-07 CSL Innovation Pty Ltd Use of an anti-Factor XII antibody for the treatment or prevention of hereditary angioedema
US20240352150A2 (en) * 2020-06-16 2024-10-24 Ningbo Comgen Biotech Co., Ltd. Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof
US20240277839A1 (en) * 2020-07-03 2024-08-22 Csl Innovation Pty Ltd. High concentration formulation and uses thereof
CN116265945B (zh) * 2022-01-05 2025-12-09 上海迈晋生物医药科技有限公司 抗凝血药物的生物学活性检测方法
WO2024255794A1 (zh) 2023-06-16 2024-12-19 舒泰神（北京）生物制药股份有限公司 特异性识别因子XIIa的抗体及其应用
AU2024291721A1 (en) 2023-07-19 2026-01-22 Regeneron Pharmaceuticals, Inc. ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901859D0 (en) * 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0534988A1 (en) * 1990-05-10 1993-04-07 Cetus Corporation Inhibitors of factor xii activation and applications thereof
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
EP1621206A1 (en) 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7112661B1 (en) * 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
US7074983B2 (en) * 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
US7414170B2 (en) * 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
US20040077538A1 (en) 2000-05-17 2004-04-22 Harvey Pollard Use of factor XIIa for treatment of hemophilia A and B and prevention of bleeding
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU2001268427B2 (en) * 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
JP2006505291A (ja) * 2002-11-08 2006-02-16 ヘマテック，エルエルシー プリオンタンパク質活性が低減されたトランスジェニック有蹄動物及びその用途
WO2004057343A2 (en) * 2002-12-20 2004-07-08 Axis-Shield Diagnostics Limited Detection or determination of variants of factor xiia
GB0229837D0 (en) * 2002-12-20 2003-01-29 Axis Shield Diagnostics Ltd Variants of activated factor XII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2333598T5 (es) 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
JP2007528721A (ja) * 2003-08-14 2007-10-18 ダイアックス コーポレイション エンドセリアーゼ−２リガンド
US7550263B2 (en) 2003-09-05 2009-06-23 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
BRPI0417916A (pt) 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
EP1598428A1 (en) * 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
JP2008515774A (ja) * 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
CA2580981C (en) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
ES2407965T3 (es) * 2004-12-23 2013-06-17 Csl Behring Gmbh Prevención de la formación y/o estabilización de trombos
GB0500487D0 (en) * 2005-01-11 2005-02-16 Axis Shield Diagnostics Ltd Forms of factor XIIa
GB0607515D0 (en) * 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
SI3028716T1 (sl) 2006-10-10 2021-01-29 Regenesance B.V. Komplementarna inhibicija za izboljšano regeneracijo živcev
EP2109457B1 (en) 2007-02-12 2016-01-06 CSL Behring GmbH Therapeutic application of kazal-type serine protease inhibitors
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
WO2009111507A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 12 binding proteins
MX2011005481A (es) * 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
ES2733067T3 (es) 2008-12-19 2019-11-27 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US8637454B2 (en) * 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
BRPI1006998A2 (pt) 2009-01-23 2015-08-25 Biogen Idec Inc Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
ES2688093T3 (es) * 2010-01-06 2018-10-30 Dyax Corp. Proteínas de unión a calicreína plasmática
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
IL269565B2 (en) * 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
JP6253578B2 (ja) * 2011-07-22 2017-12-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用

Also Published As

Publication number Publication date
WO2013014092A1 (en) 2013-01-31
KR20140054112A (ko) 2014-05-08
US9856325B2 (en) 2018-01-02
HK1198334A1 (en) 2015-04-02
US20140199361A1 (en) 2014-07-17
NZ619385A (en) 2016-07-29
AU2012289001A1 (en) 2013-05-02
HUS2500028I1 (hu) 2025-07-28
JP6253578B2 (ja) 2017-12-27
CN103687878B (zh) 2018-01-09
HUE070002T2 (hu) 2025-04-28
ES3005912T3 (en) 2025-03-17
BR112014001104A2 (pt) 2017-12-12
US20200062863A1 (en) 2020-02-27
IL230564B2 (en) 2023-09-01
CN103687878A (zh) 2014-03-26
HRP20250164T1 (hr) 2025-04-11
IL230564B1 (en) 2023-05-01
IL230564A0 (en) 2014-03-31
BR112014001104B1 (pt) 2022-12-06
US20170137536A1 (en) 2017-05-18
CA2841185C (en) 2021-05-25
MX347454B (es) 2017-04-27
PT2734552T (pt) 2025-01-29
RS66465B1 (sr) 2025-02-28
US9518127B2 (en) 2016-12-13
NL301332I2 (nl) 2025-09-10
US20180134806A1 (en) 2018-05-17
US9856326B2 (en) 2018-01-02
US11345759B2 (en) 2022-05-31
RU2660370C2 (ru) 2018-07-05
FI2734552T3 (fi) 2025-02-12
SI2734552T1 (sl) 2025-03-31
FIC20250024I1 (fi) 2025-07-08
MX2014000363A (es) 2014-03-27
FR25C1026I1 (fr) 2025-09-19
LTPA2025524I1 (pl) 2025-07-10
KR102042982B1 (ko) 2019-11-11
NO2025031I1 (no) 2025-07-09
EP4516811A3 (en) 2025-03-26
EP2734552A1 (en) 2014-05-28
US20170121423A1 (en) 2017-05-04
US10513560B2 (en) 2019-12-24
IL291613A (en) 2022-05-01
AU2012289001B2 (en) 2016-03-03
EP2734552B1 (en) 2024-11-13
EP4516811A2 (en) 2025-03-05
IL291613B2 (en) 2025-12-01
SMT202500041T1 (it) 2025-03-12
CY2025019I1 (el) 2026-02-25
DK2734552T3 (da) 2024-12-09
JP2014523253A (ja) 2014-09-11
RU2014106652A (ru) 2015-08-27
LT2734552T (lt) 2025-01-10
IL291613B1 (en) 2025-08-01
CA2841185A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
HUS2500028I1 (hu) XII/XIIa faktor elleni gátló monoklonális ellenanyagok és alkalmazásaik
HUS2300021I1 (hu) Anti-IL-36R antitestek
LTPA2021001I1 (lt) Anti-PD-L1 antikūnai ir jų panaudojimas
DK4459282T3 (da) Monoklonalt interleukin-31-antistof
DK2521736T3 (da) Humaniserede antistoffer
IL231777A0 (en) Antibodies against tl1a and uses thereof
PL2488551T3 (pl) Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
IL221408B (en) Monoclonal antibodies against c-met
DK2668210T3 (da) Anti-kit antistoffer og anvendelser deraf
BR112013022797A2 (pt) anticorpos anti-ctla4 humanizados
PL2731677T3 (pl) Przeciwciała wiążące się z OX40 i ich zastosowania
CO6811812A2 (es) Anticuerpo anti-b7-h3
CR20140127A (es) Anticuerpo anti-abtcr
CY1127385T1 (el) Ανασταλτικα μονοκλωνικα αντισωματα εναντι του παραγοντα xii/xiia και οι χρησεις τους
HUE036079T2 (hu) Új anti-humán NGF antitest
LT2742068T (lt) Nauji antikūnai prieš fosforilcholiną
CO6841994A2 (es) Anticuerpos